Xinteza API

Xinteza API is an innovative biosynthesis technology company focused on producing cannabinoids and psychoactive ingredients without cannabis plants.

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2019
Last updated 2026-07-20
Total raised
Last: Undisclosed Round 2020-01
Stage
Seed
Founded
2019
Headcount
4
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Xinteza API Ltd. is an innovative biosynthesis technology company based in Tel Aviv, Israel. The company is engaged in the discovery and development of novel genes, enzymes, and genetic pathways for the biosynthesis of cannabinoids and psychoactive ingredients, and the development of their bio-production methods. Xinteza operates under an exclusive license from the Weizmann Institute of Science, with research led by Prof. Asaph Aharoni. Their goal is to revolutionize the commercial-scale synthesis of ultra-pure natural lab-made major, minor, and modified cannabinoids, and key psychedelics, making the production of innovative Active Pharmaceutical Ingredients (APIs) and Active Ingredients (AIs) for high-end CPG and pharma more accessible.

Funding history · 1 round · — total

2019-12
Undisclosed Round Undisclosed

Headcount over time

From 2 (2022-02) to 4 (2025-10) · +2 (+100%) · 5 points · source: Finder history + radar grounding
50 2022-02 2025-10

Q&A

What is Xinteza API's primary business?
Xinteza API is developing advanced proprietary biosynthesis and bioextraction technologies for producing cannabinoid-based active pharmaceutical ingredients (APIs) for the pharmaceutical and food industries.
When was Xinteza API founded?
Xinteza API was founded in March 2019.
What is Xinteza API's current employee count?
Xinteza API has 1-10 employees.
What is Xinteza API's primary sector?
Xinteza API's primary sector is Health Tech & Life Sciences.
What is Xinteza API's current funding stage?
Xinteza API is currently in the Seed funding stage.
Does Xinteza API hold any patents?
Yes, Xinteza API holds at least one patent and is building a portfolio of related IP and patents.
What is the nature of Xinteza API's intellectual property?
Xinteza API holds an exclusive license for cannabinoids and psychoactives from the Weizmann Institute and is developing a portfolio of related IP and patents.
What is Xinteza API's product stage?
Xinteza API is currently in the R&D product stage.

Team · 4

Asaph Aharoni
Founder · Scientific Co-Founder
Alon Gal
Founder · Co-Founder, CEO
Zohar Koren
Founder · Co-Founder, CTO
Ron Klein
Founder · Co-Founder, COO & CFO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
BiologicalsMoleculesGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

natural-active-ingredientsagtechmedical-cannabisplant-genomicsapicannabispharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitexinteza.com
LinkedInlinkedin.com/company/77669925

Identifiers & details

Legal nameXinteza API Ltd.
Founded2019-12
Employees (exact)4

Radar intelligence

Web history (Wayback)

Domainxinteza.com

Certificate / subdomain footprint

Subdomains3

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515997211
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2019-03-17
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events2 — annual_report (1), people (1)
Registered addressרובינא חנה 7 תל אביב - יפו

Recent registry events

DateEvent
2026-06-22דו~ח שנתי
2025-09-09עדכון בעלי תפקידים